36314-97-3

Basic information

• Product Name: 2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE
• Synonyms: IFLAB-BB F2108-0197;2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE;4-Chloro-6-phenyl-2-pyrimidinamine;2-Amino-4-phenyl-6-chloropyrimidine;2-Pyrimidinamine, 4-chloro-6-phenyl-;4-Chloro-6-phenyl-pyrimidin-2-ylamine
• CAS NO: 36314-97-3
• Molecular Formula: C₁₀H₈ClN₃
• Molecular Weight: 205.64
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 36314-97-3.mol

Chemical Properties

• Boiling Point: 433.1 °C at 760 mmHg
• Flash Point: 215.8 °C
• Appearance: /
• Density: 1.323 g/cm³
• Vapor Pressure: 1.05E-07mmHg at 25°C
• Refractive Index: 1.642
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE(36314-97-3)
• EPA Substance Registry System: 2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE(36314-97-3)

Safety Data

• Hazardous Substances Data: 36314-97-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs targeting a range of diseases, making it a valuable component in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE serves as an intermediate for the production of agrochemicals. Its incorporation into these compounds can contribute to the creation of effective pesticides and other agricultural products.
Used in Organic Synthesis:
2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE is utilized as a building block in the preparation of novel organic compounds. Its versatile structure facilitates the synthesis of a variety of organic molecules, expanding the scope of chemical research and development.
It is crucial to handle and use 2-AMINO-4-CHLORO-6-PHENYLPYRIMIDINE with care, adhering to proper safety procedures and guidelines to ensure the safety of individuals and the environment.

InChI:InChI=1/C10H8ClN3/c11-9-6-8(13-10(12)14-9)7-4-2-1-3-5-7/h1-6H,(H2,12,13,14)

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 98-80-6 phenylboronic acid 
• 56741-94-7 2-amino-6-phenyl-3H-pyrimidin-4-one 
• 56741-94-7 2-amino-4-hydroxy-6-phenylpyrimidine 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 

Downstream Products

• 76369-29-4 6,N⁴-diphenyl-pyrimidine-2,4-diyldiamine 
• 55038-79-4 N₄-methyl-6-phenylpyrimidine-2,4-diamine 
• 78222-45-4 2-amino-4-(2',4'-dichlorophenoxy)-6-phenylpyrimidine 
• 106791-93-9 2-amino-5-bromo-4-chloro-6-phenylpyrimidine 
• 76369-32-9 N⁴-(4-chloro-phenyl)-6-phenyl-pyrimidine-2,4-diyldiamine 
• 78222-48-7 2-amino-5-bromo-1-hydroxy-6-phenyl-4-pyrimidinone 
• 78222-46-5 2-amino-4-(2',4'-dichlorophenoxy)-6-phenylpyrimidine-1-oxide 
• 569658-29-3 N-(2-amino-6-phenyl-4-pyrimidinyl)-N-[3,5-dichloro-4-(4-pyridinylsulfanyl)phenyl]amine 
• 881193-21-1 4-(4-fluoro-phenylsulfanyl)-6-phenyl-pyrimidin-2-ylamine 
• 881193-01-7 N₄-(3-chloro-4-methoxy-phenyl)-6-phenyl-pyrimidine-2,4-diamine 
• 1028327-66-3 VUF 10460 
• 1186410-74-1 4-hydrazinyl-6-phenylpyrimidin-2-amine 
• 1186410-27-4 5-amino-7-phenyl-2-(phenylmethyl)-1,2,4-triazolo[4,3-c]pyrimidin-3(2H)-one 
• 1186410-75-2 C₁₇H₁₇N₅ 

Relevant articles and documents

TRIAZOLE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS

Described herein are triazole compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER

Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER

Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be

TRIAZOLONE COMPOUNDS

Described herein are triazolone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be

TRIAZOLONE COMPOUNDS

Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): or and pharmaceutically acceptable salts thereof, wherein, R1, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Synthesis and Investigation of Phthalazinones as Antitubercular Agents

A series of 2- and 7-substituted phthalazinones was synthesised and their potential as anti-tubercular drugs assessed via Mycobacterium tuberculosis (mc26230) growth inhibition assays. All phthalazinones tested showed growth inhibitory activity (MIC 100 μm), and those compounds containing lipophilic and electron-withdrawing groups generally exhibited better anti-tubercular activity. Several lead compounds were identified, including 7-((2-amino-6-(4-fluorophenyl)pyrimidin-4-yl)amino)-2-heptylphthalazin-1(2H)-one (MIC=1.6 μm), 4-tertbutylphthalazin-2(1H)-one (MIC=3 μm), and 7-nitro-phthalazin-1(2H)-one (MIC=3 μm). Mode of action studies indicated that selected pyrimidinyl-phthalazinones may interfere with NADH oxidation, however, the mode of action of the lead compound is independent of this enzyme. MIC=minimum inhibitory concentration.

Triazolopyrimidine derivative, preparation method thereof, and application thereof in medicines

The invention relates to a triazolopyrimidine derivative, a preparation method thereof, and an application thereof in medicines. In particular, the invention relates to the triazolopyrimidine derivative represented as the general formula (I), a preparation method thereof, a medicine composition containing the derivative, and an application of the derivative as a treatment agent, especially an application as an A2a receptor antagonist, and an application in preparation of a medicine for relieving symptoms and diseases by inhibiting the A2a receptor; wherein the substituent groups in the generalformula (I) are defined as the specification.

Influence of the C-5 substitution in polysubstituted pyrimidines on inhibition of prostaglandin E2 production

As a part of a broader structure-activity relationship study of substituted 2-aminopyrimidines, the influence of the C-5 substitution on inhibition of prostaglandin E2 (PGE2) production was studied. Thirty compounds were prepared sta